AZELNIDIPINE COMBINED WITH ANGIOTENSIN RECEPTOR BLOCKER CAN RESTORE SYMPATHETIC ACTIVITY
Not Applicable
- Conditions
- Chronic Kidney Disease (CKD)
- Registration Number
- JPRN-UMIN000009158
- Lead Sponsor
- Division of Nephrology, Nafoya City University Hospital
- Brief Summary
Means of all normal-to-normal intervals over 24 h (p<0.0001) and DC (p=0.002) increased, and Lambda (p=0.001) decreased regardless of gender, age, renal function or blood pressure, while no significant changes were observed in the other HRVs. Reduction of Lambda is useful to assess the effect of sympathoinhibitory treatment. J Renin Angiotensin Aldosterone Syst. 2016 Apr 18;17(2):1470320316643905
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) polycystic kidney disease 2) arrhythmia 3) known history of angina pectoris, myocardial infarction, heart failure, stroke, or TIA
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease in LF/HF, increase in HF and the attenuation of the non-Gaussianity index during 8-wk treatment with ARB/CCB
- Secondary Outcome Measures
Name Time Method changes in proteinuria (mg/gCre) and office blood pressure